CN108014131B - 锌-γ-PGA组合物和治疗癌症的方法 - Google Patents

锌-γ-PGA组合物和治疗癌症的方法 Download PDF

Info

Publication number
CN108014131B
CN108014131B CN201711108631.5A CN201711108631A CN108014131B CN 108014131 B CN108014131 B CN 108014131B CN 201711108631 A CN201711108631 A CN 201711108631A CN 108014131 B CN108014131 B CN 108014131B
Authority
CN
China
Prior art keywords
dosage form
zinc
pga
tumor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711108631.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108014131A (zh
Inventor
郑振赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhai Lunix Private Ltd
Original Assignee
Xylonix IP Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix IP Holdings Pte Ltd filed Critical Xylonix IP Holdings Pte Ltd
Priority to CN202310311382.9A priority Critical patent/CN116350658A/zh
Publication of CN108014131A publication Critical patent/CN108014131A/zh
Application granted granted Critical
Publication of CN108014131B publication Critical patent/CN108014131B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201711108631.5A 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法 Active CN108014131B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310311382.9A CN116350658A (zh) 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201609131Y 2016-11-01
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310311382.9A Division CN116350658A (zh) 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法

Publications (2)

Publication Number Publication Date
CN108014131A CN108014131A (zh) 2018-05-11
CN108014131B true CN108014131B (zh) 2023-04-14

Family

ID=60327362

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711108631.5A Active CN108014131B (zh) 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法
CN202310311382.9A Pending CN116350658A (zh) 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310311382.9A Pending CN116350658A (zh) 2016-11-01 2017-11-01 锌-γ-PGA组合物和治疗癌症的方法

Country Status (10)

Country Link
US (2) US11944640B2 (enExample)
EP (1) EP3534914B1 (enExample)
JP (2) JP7083835B2 (enExample)
KR (1) KR102616690B1 (enExample)
CN (2) CN108014131B (enExample)
AU (2) AU2017354787B2 (enExample)
CA (1) CA3042383A1 (enExample)
MX (2) MX395613B (enExample)
SG (3) SG10201609131YA (enExample)
WO (1) WO2018084806A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2020013883A (es) * 2018-06-22 2021-05-27 Xylonix Ip Holdings Pte Ltd Tratamientos oncológicos con agentes de zinc.
KR102094182B1 (ko) * 2018-06-28 2020-03-30 주식회사 알랙스탠드 아연 함유 수용성 폴리글루타믹산 복합체 조성물
EP4308166A1 (en) 2021-03-18 2024-01-24 Xylonix Pte. Ltd. Pharmaceutical polymer conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897122A (en) 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
JP2712583B2 (ja) 1989-06-28 1998-02-16 味の素株式会社 易吸収性ミネラル含有飲食物
JP3551149B2 (ja) 1992-03-24 2004-08-04 味の素株式会社 易吸収性ミネラル含有組成物及びそれを含有する飲食品
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
EP0605757B1 (en) 1992-11-25 2001-08-16 Ajinomoto Co., Inc. Compositions and goods containing minerals and poly-gamma-glutamic acid
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
IT1275923B1 (it) 1995-03-16 1997-10-24 Valpharma Sa Formulazioni gastroresistenti contenenti zinco
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH11313618A (ja) 1998-05-06 1999-11-16 Yoshio Inoue 胃にやさしい家畜用ミネラル（亜鉛）製剤及びその製造法
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
WO2003061598A2 (en) 2002-01-25 2003-07-31 The University Of Georgia Research Foundation, Inc. Solenopsin a, b and analogs as novel angiogenesis inhibitors
WO2004080210A1 (en) 2003-03-14 2004-09-23 Boehringer Ingelheim Danmark A/S Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea
KR100498812B1 (ko) 2003-07-10 2005-07-01 주식회사 바이오리더스 초고분자량의 폴리감마글루탐산을 함유하는 미네랄의 체내흡수 촉진용 조성물
JP4457641B2 (ja) 2003-11-10 2010-04-28 味の素株式会社 ゼラチンカプセル
JP5162812B2 (ja) 2004-07-08 2013-03-13 大正製薬株式会社 亜鉛含有経口投与用組成物
ES2392544T3 (es) 2005-06-07 2012-12-11 Yale University Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT
JPWO2007043606A1 (ja) * 2005-10-12 2009-04-16 株式会社ジェノラックＢｌ アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤
WO2007109290A2 (en) 2006-03-20 2007-09-27 Pharmacyclics, Inc. Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
JP2010526159A (ja) 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
CA2686604A1 (en) 2007-05-09 2008-11-20 Salutria Pharmaceuticals Llc Spiro compounds for treatment of inflammatory disorders
EP2155253A2 (en) 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
JP2012523413A (ja) 2009-04-10 2012-10-04 サイプレス ファーマシューティカルズ， インコーポレイテッド ホスフェート結合性マグネシウム塩およびその使用
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CN101716180B (zh) 2009-11-06 2013-04-24 广西强寿药业集团有限公司 一种组合补充锌、钙药物及其制备方法
US20110117210A1 (en) 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
CA2800235C (en) 2010-03-10 2018-10-16 Lupin Limited Rifaximin ready-to-use suspension
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
ES2646927T3 (es) 2012-11-21 2017-12-18 KBS Research, LLC Suplementos herbales y métodos de uso de los mismos
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
EP2978423A4 (en) 2013-03-28 2016-08-24 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
BR112015024537B1 (pt) 2013-04-12 2022-09-06 Ned Biosystems, Inc Uso de (i) ciclofosfamida, (ii) metformina, (iii) curcumina, (iv) melatonina, (v) naltrexona, (vi) ácido alfa lipoico e (vii) genisteína e combinação no tratamento de câncer
CN105143242A (zh) 2013-04-26 2015-12-09 日东电工株式会社 大规模制备聚(谷氨酰基-谷氨酸盐)偶联物的方法
WO2015009699A1 (en) 2013-07-15 2015-01-22 Ketter Patrick Methods and compositions to prevent or treat bacterial infections
JP2016069303A (ja) 2014-09-29 2016-05-09 タカラバイオ株式会社 フコイダンを有効成分とする脱毛抑制用組成物
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
KR102467968B1 (ko) 2014-10-08 2022-11-16 신세틱 바이오로직스, 인코퍼레이티드 베타-락타마제 제형 및 이의 용도
US20160122739A1 (en) 2014-10-31 2016-05-05 Wisconsin Alumni Research Foundation Factor ix variants and methods of use therefor
WO2016088816A1 (ja) 2014-12-03 2016-06-09 ノーベルファーマ株式会社 酢酸亜鉛水和物錠及びその製造方法
CN109890405A (zh) 2016-08-19 2019-06-14 布鲁克林免疫治疗有限公司 Pd-1/pd-l1抑制剂和/或ctla-4抑制剂与含有多种细胞因子组分的生物制剂用于治疗癌症的用途
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2020013883A (es) 2018-06-22 2021-05-27 Xylonix Ip Holdings Pte Ltd Tratamientos oncológicos con agentes de zinc.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101233121A (zh) * 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A Zinc(II)/poly(gamma-glutamic acid) complex as an oral therapeutic for the treatment of type-2 diabetic KKAy mice;Subarna et al.;《Macromol Biosci》;20090310;第9卷(第3期);279-286 *
Subarna et al..A Zinc(II)/poly(gamma-glutamic acid) complex as an oral therapeutic for the treatment of type-2 diabetic KKAy mice.《Macromol Biosci》.2009,第9卷(第3期),279-286. *
Zinc pyrithione induces ERK- and PKC-dependent necrosis distinct from;Robert et al.;《Biochim Biophys Acta》;20110913;第1823卷(第2期);544-557 *
余元勋等主编.NF-KB通路与肿瘤的关系.《中国分子肝癌学》.安徽科学技术出版社,2016,157. *
姚日生主编.聚谷氨酸.《药用高分子材料 第2版》.北京化学工业出版社,2008,198. *

Also Published As

Publication number Publication date
MX2019005104A (es) 2019-10-30
MX2022011372A (es) 2022-10-10
EP3534914A1 (en) 2019-09-11
KR102616690B1 (ko) 2023-12-21
EP3534914B1 (en) 2025-07-16
AU2023203220B2 (en) 2025-07-31
CA3042383A1 (en) 2018-05-11
CN108014131A (zh) 2018-05-11
US11944640B2 (en) 2024-04-02
CN116350658A (zh) 2023-06-30
JP7083835B2 (ja) 2022-06-13
MX395613B (es) 2025-03-25
EP3534914C0 (en) 2025-07-16
WO2018084806A1 (en) 2018-05-11
SG11201903753QA (en) 2019-05-30
SG10201609131YA (en) 2018-06-28
US20250025496A1 (en) 2025-01-23
US20190255104A1 (en) 2019-08-22
JP2022116255A (ja) 2022-08-09
AU2017354787A1 (en) 2019-05-16
AU2017354787B2 (en) 2023-02-23
JP2019534330A (ja) 2019-11-28
AU2023203220A1 (en) 2023-06-22
JP7466822B2 (ja) 2024-04-15
KR20190120159A (ko) 2019-10-23
SG10202013112YA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JP7466822B2 (ja) 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法
Choukaife et al. Current advances in chitosan nanoparticles based oral drug delivery for colorectal cancer treatment
Guan et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy
US11471422B2 (en) Stealth, targeted nanoparticles (STN) for oral drug delivery
US8785380B2 (en) Formulation containing curcuminoids exhibiting enhanced bioavailability
JP2009537572A (ja) ２０（Ｒ）−人参サポニン（ジンセノサイド）Ｒｇ３薬用組成物水溶液及びその調製方法
CN110087632A (zh) 乳酸钙组合物和使用方法
WO2020227437A1 (en) Sustained release solid dosage forms for modulating the colonic microbiome
JP2025148479A (ja) ガンマ－ポリグルタミン酸および亜鉛組成物
KR102725852B1 (ko) 알파-폴리글루탐산-아연을 포함하는 암 치료용 조성물
CA2544404A1 (en) Novel nimesulide compositions
HK40035636A (en) Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
KR100882873B1 (ko) 카테킨 함유 리포솜을 포집하는 펙틴 전달체
JP2016537428A (ja) エフェドラ・アラタ抽出物及びその使用方法
EP4142718A1 (en) Modified release pharmaceutical formulation comprising hydroxypropyl cellulose

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240319

Address after: Montbatten Road, Singapore

Patentee after: Zhai Lunix Private Ltd.

Country or region after: Singapore

Address before: Singapore International Building

Patentee before: Xylonix IP Holdings Pte. Ltd.

Country or region before: Singapore